DACS
DNTH icon

Dymon Asia Capital (Singapore)’s Dianthus Therapeutics DNTH Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,600
Closed -$638K – 265
2026
Q1 		$638K Buy
+7,600
New +$440K 0.07% 203

Other funds holding DNTH

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
PFA
Peak Financial Advisors Denver, Colorado $242M AUM 19.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
FHC
First Horizon Corporation Memphis, Tennessee $2.6B AUM 23.72% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s DNTH Position: Q2 2026 in Review

Dymon Asia Capital (Singapore) sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 7,600 shares — an estimated $638K sold.

Dymon Asia Capital (Singapore) first reported a position in DNTH in Q1 2026 and held it in 1 quarter. The position peaked at $638K in Q1 2026. 21 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Dymon Asia Capital (Singapore) reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Dymon Asia Capital (Singapore) sold 7,600 Dianthus Therapeutics shares in Q2 2026, an estimated $638K.
  • Dymon Asia Capital (Singapore) first reported a position in Dianthus Therapeutics in Q1 2026 and held it in 1 quarter.
  • Dymon Asia Capital (Singapore)'s Dianthus Therapeutics position peaked at $638K in Q1 2026.
  • 21 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q2 2026, filed 23 Jul 2026.